(Q38128112)

29 August 2017

title

Effectiveness of meningococcal serogroup C vaccine programmes (English)

1 reference

29 August 2017

1 reference

Caroline Trotter

3

0 references

Raquel Abad

object named as

Raquel Abad

2

0 references

Ray Borrow

1

object named as

Ray Borrow

1 reference

29 August 2017

author name string

Fiona R M van der Klis

4

1 reference

29 August 2017

Julio A Vazquez

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

9 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

31

1 reference

29 August 2017

issue

41

1 reference

29 August 2017

page(s)

4477-4486

1 reference

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

29 August 2017

cites work

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

inferred from DOI database lookup

7 January 2021

based on heuristic

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Update on meningococcal disease with emphasis on pathogenesis and clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Prevention of meningococcal serogroup C disease by NeisVac-C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

"Herd immunity": a rough guide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 mont

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Meningococcal vaccines in Canada: An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.083

10.1016/J.VACCINE.2013.07.083

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference